Sharjah24 – Reuters: AstraZeneca said on Monday the European Medicines Agency (EMA) had recommended approving a medicine from its Alexion unit for treating a rare, deadly blood disorder in children and adolescents aged up to 18 years.
The drugmaker, which recently completed its $39 billion buyout of U.S.-based Alexion, said the drug Ultomiris had been given a positive opinion for paroxysmal nocturnal haemoglobinuria by the human medicines committee of the EMA.
For an optimal experience, please
